PubMed Health⌕ Search

Biomedical subjects

Larry J Diaz-Sandoval

Publications and source records attributed to Larry J Diaz-Sandoval.

5 recordsLinked to original sources
PubMed2005

Optical coherence tomography as a tool for percutaneous coronary interventions.

This study was performed to demonstrate the ability of intravascular optical coherence tomography (OCT) to identify characteristic vascular responses to percutaneous coronary interventions (PCI). OCT provides cross-sectional images of tissue in situ at approximately 10 microm, rendering detailed structural information. Intravascular ultrasound and OCT images were obtained from 10 patients before and after PCI. Images were evaluated to identify balloon-induced dissections/disruptions, thrombus, cutting balloon-induced vascular changes, tissue protrusion, stent apposition and symmetry, and intimal hyperplasia. The disrupted intima, intraluminal thrombus, depth of balloon-induced dissections, cutting balloon cuts, tissue prolapse, underdeployed struts, and intimal hyperplasia were all noticed with OCT. This is the first report of the use of OCT to identify in vivo human intracoronary pathology after PCI.

Angioplasty, Balloon, Coronary↗
PubMed2003

Gene therapy for cardiovascular angiogenesis.

Atherosclerosis and endothelial dysfunction are responsible for the pathophysiologic basis of the spectrum of cardiovascular disorders including ischaemic heart disease (IHD), the leading cause of morbidity and mortality in the US. There have been major advances, including the use of pharmacotherapy, coronary and peripheral percutaneous transluminal interventions (PTI), coronary and peripheral bypass surgery and primary/secondary prevention measures. There are, however, multiple unmet needs: IHD refractory to medical therapy and unsuitable for revascularisation; critical limb ischaemia unsuitable for PTI or surgery; restenosis; ischaemic/diabetic neuropathy and heart failure. Cardiovascular gene therapy (GT) with vascular endothelial growth factor (VEGF) has yielded improved perfusion and reduced ischaemia in preclinical models of IHD. Several preclinical studies and Phase I and II clinical trials have shown the safety and therapeutic potential of GT in the treatment of IHD, peripheral arterial disease (PAD), restenosis, and ischaemic and diabetic neuropathy, pointing to the need for Phase III clinical trials.

Animals↗